Medium‐term response characterisation and risk factor analysis of botulinum toxin type A in the management of spasticity in children with cerebral palsy
- 1 November 1999
- journal article
- Published by Wiley in European Journal of Neurology
- Vol. 6 (S4) , s37-s45
- https://doi.org/10.1111/j.1468-1331.1999.tb00033.x
Abstract
No abstract availableKeywords
This publication has 29 references indexed in Scilit:
- Objective measurement of clinical findings in the use of botulinum toxin type A for the management of children with cerebral palsyEuropean Journal of Neurology, 1999
- Botulinum A Toxin Therapy: Neutralizing and Nonneutralizing Antibodies—Therapeutic ConsequencesExperimental Neurology, 1997
- Botulinum toxin A in the hemiplegia upper limb: a double‐blind trialDevelopmental Medicine and Child Neurology, 1997
- Injection of botulinum A toxin into the gastrocnemius muscle of patients with cerebral palsy: a 3-dimensional motion analysis studyGait & Posture, 1996
- Topical Review: Baclofen in the Treatment of Cerebral PalsyJournal of Child Neurology, 1996
- BOTULINUM TOXIN IN THE MANAGEMENT OF THE LOWER LIMB IN CEREBRAL PALSYDevelopmental Medicine and Child Neurology, 1994
- BOTUNUM TOXIN A PREVENTS THE DEVELOPMENT OF CONTRACTURES IN THE HEREDITARY SPASTC MOUSEDevelopmental Medicine and Child Neurology, 1994
- Complications with Selective Posterior RhizotomyPediatric Neurosurgery, 1992
- THE GROSS MOTOR FUNCTION MEASURE: A MEANS TO EVALUATE THE EFFECTS OF PHYSICAL THERAPYDevelopmental Medicine and Child Neurology, 1989
- Acceptors for botulinum neurotoxin reside on motor nerve terminals and mediate its internalizationNature, 1984